Stay up-to-date on the world of marine Omega-3s and everything Epax.
US FDA Announcement on
Omega-3 Qualified Health Claim!
On June 19, the US Food and Drug Administration decided to allow a qualified health claim (QHC) linking EPA and DHA to a reduction in blood pressure. The QHC came after a thorough evaluation of GOED's August 2014 health claim petition and is a huge leap forward for both the industry and the general population. According to the American Heart Association, more than 100 million American adults have high blood pressure, leading to increased risk of heart attacks and strokes. Further, the FDA updated its safety review to examine more recent evidence regarding the effects of consuming EPA and DHA at levels above 3 grams per day on glycemic control, blood cholesterol, and risk of excessive bleeding, and concluded levels up to 5 grams per day as safe.
The Epax production facility is located relatively close to the city centre of Ålesund, so Epax has a special responsibility to find solutions that benefits the local environment. One of our focus areas is reducing local truck traffic, and the air pollution from that traffic. We have now achieved a dramatic reduction in road transport by shifting the majority of our by-product shipments to sea, and by setting up production of our own biofuel.
Shipment by sea has a significantly lower carbon footprint than that of trucks. So in addition to reduced local pollution and congestion on the roads, we benefit from the efficiency of scale in that ships burn far less fuel per ton of by-products transported. This effort is in line with recommendations made by the UN (UNCTAD: https://unctad.org/meetings/en/SessionalDocuments/cimem7d17_en.pdf).
Our biofuel is made from the by-products of our Omega-3 production, and burns extremely clean, with very little dust resulting from the combustion. And it comes of course from a renewable source.
Epax R&D Breakthrough
Taking Molecular Distillation to the Next Level
Molecular distillation is, for many consumers, synonymous with product quality and purity. Most people connect the term with the removal of environmental impurities in fish oils, but molecular distillation also plays a key role in the up-concentration of EPA and DHA content. Due to the mild nature of the technology, Epax considers molecular distillation to be the best way of increasing EPA and DHA content without triggering the oxidation process in the oil, and inadvertently creating unwanted, and potentially harmful, oxidative by-products such as trans fatty acids, oligomers and polymers. We have now made a great technological breakthrough in the quest to increase the maximum achievable concentration levels, reaching concentrations up to 700 mg/g of EPA/DHA. Contact your Epax representative for further details!
Join us at
With Vitafoods Europe fast approaching, we would like to remind all customers and friends of Epax of the annual stand event taking place on Wednesday May 8th from 16:00-17:30 (4-5:30 pm), stand nr. I92 (on the main aisle). The whole Epax team is looking forward to it!
Upgrade to Epax:
As part of an increased focus on organoleptic values, Epax has been an active participant in and contributor to the research project ‘QOMEGA-3 – Sensory Industry Standard for Marine Oils’, a project run by Norwegian research service company Møreforsking, funded by the Norwegian Research Fund (FHF).
After a 2-year process of actively testing and mapping fish oil samples from Norwegian manufacturers, Møreforsking suggests three quality categories; Gold, Silver, and Regular.
Our premium TGN concentrates have repeatedly received high scores and Gold Standard in the testing, and we are now initiating capital investments in our production facility to be able to eventually include sensory standards as part of our product specifications.
Read more about the project (Norwegian text) here!
Natural Foods Merchandiser:
Consumers Value Transparent Companies
Leading trade magazine Natural Products Merchandiser report, based on market data from Accenture, that 'businesses that show commitment to a greater mission are more likely to influence and attract consumers'. Further, they state that the majority of consumers value companies that use good quality ingredients, treat employees well, and believe in reducing plastics and improving the environment. Read the full article here
GOED Comments on Estimated CVD Deaths Caused by
Low Seafood Intake
Interesting analysis by Aldo Bernasconi at The Global Organization for EPA and DHA Omega-3s (GOED). According to the data from the Global Burden of Disease Study, in 2016, in Western, Central and Eastern Europe, and Central Asia, an estimated 227,000 CVD deaths were caused by seafood omega-3 intakes under 250 mg/day!! Watch Aldo's video for full analysis!
At Epax, we have a long and proud tradition of supporting the scientific community with study medication. We do this to help develop new and independent science on the wonderful effects of Omega-3. We're excited and grateful that the latest study to publish, by Howe et. al., has been picked up by leading trade magazine NutraIngredients! Read the article here!
On February 20-22 2019, NutraIngredients will host the first ever NutraIngredients Omega-3 Summit (in association with GOED). The event will take place in Singapore, promising to 'bring the international omega-3 community to Asia-Pacific, and take the insights from the region to the world'. At Epax, we are excited to support what we are certain will be a top-notch Omega-3 event, and we are looking forward to 3 educational and fun days!
Epax' owner company Pelagia, a leading producer of pelagic fish products for human consumption, and an important supplier of essential ingredients in all kinds of fish- and animal feed; protein concentrate, fishmeal, and fish oil, recently published its Q3 results. Visit Pelagia's website for more information!
Omega-3 Fatty Acids:
Correct Form of Measurement
The Global Organization for EPA and DHA Omega-3s (GOED) recently released an industry advisory on the correct way of measuring EPA and DHA. Whilst Area % historically was the standard measurement of the Omega-3 fatty acid content, Epax chose to replace this for the far more accurate weight measurement (mg/g) several years ago. In fact, all new products launched by Epax the past 5 years solely use mg/g unless where an addition of A% has been specifically required by the customer. We support GOED's effort to establish mg/g as the standard form of measurement. The new industry advisory can be found here.
GOED Voluntary Monograph
Reduced Limit for Lead
The members of GOED recently voted to reduce the maximum limit on lead from 0.1 to 0.05 mg/kg in the GOED Voluntary Monograph. In order to furter support a positive development for the Omega-3 industry, Epax was one of the members voting for this change. The new limit will be valid from March 1, 2019.
For Epax’ products and customers there will be no specification change required, as we already implemented a maximum limit of 0.025 mg/kg back in 2009-2010.
Epax to present at
Nordic Lipidforum Seminar
Our R&D Manager Iren Stoknes and our Product Marketing Manager Sarah Christianslund will present at Nordic Lipidforum's seminar 'High Quality Lipid Products – lipid oxidation and sensory properties'.
The Global Organization for EPA and DHA Omega-3s (GOED) has relaunched its Omega-3 science hub 'Fats of Life'. This site is specifically designed for healthcare professionals, offering an easy way of accessing high-quality scientific data on the use of EPA and DHA Omega-3 for various health conditions/concerns.
We currently have 2 positions open at our facility in Ålesund, Norway. Join one of the best teams in the Omega-3 industry!
Epax to exhibit at Vitafoods Asia
Epax Norway AS is set to exhibit at Vitafoods Asia September 11-12 at the Sands Expo & Convention Centre at Marina Bay Sands in Singapore. Visit us at stand J30 on the GOED Pavilion for a chat about Omega-3!
New Omega-3 research
PUFA level and acute venous thromboembolism
Hiki M et al. have studied the significance of serum polyunsaturated fatty acid level imbalance in patients with acute venous thromboembolism, and our key takeway is that high serum AA levels and low EPA levels are associated with the development of acute VTE, suggesting that the imbalance of PUFAs may be a potential therapeutic target for preventing acute VTE.
Background: Polyunsaturated fatty acids (PUFAs) take part in various biological events linked to the pathogenesis of venous thromboembolism (VTE), including inflammation, endothelial dysfunction, and hypercoagulability. Several studies have demonstrated the association between PUFAs and the occurrence of VTE.
Design: 45 patients with acute VTE were enrolled to examine their PUFA levels. 37 age-, gender-, and body mass index-matched healthy volunteers were controls. Serum omega 3 (eicosapentaenoic acid: EPA and docosahexaenoic acid: DHA) and omega 6 (dihomogammalinolenic acid: DGLA and arachidonic acid: AA) fatty acids levels were measured within 24 h of admission.
Results: Patients with VTE showed significantly higher AA and lower EPA levels, and lower EPA/AA ratios than the controls. Multivariate analysis revealed that AA was an independent marker for VTE. When the patients were divided based on their median age (58 years old) the younger patients with VTE showed significantly lower EPA/AA levels than their age-matched controls, whereas older patients with VTE showed a significantly higher AA/DGLA levels than the older controls.
Source: Journal of atherosclerosis and thrombosis 2017;24:1016-1022